UBC Faculty Research and Publications

CD34 is required for the infiltration of inflammatory cells into the mouse colon during DSS-induced colitis Maltby, Steven; Wohlfarth, Carolin; Hughes, Michael R; McNagny, Kelly M Nov 26, 2010

Your browser doesn't seem to have a PDF viewer, please download the PDF to view this item.

Item Metadata


52383-13223_2010_Article_208.pdf [ 148.08kB ]
JSON: 52383-1.0223337.json
JSON-LD: 52383-1.0223337-ld.json
RDF/XML (Pretty): 52383-1.0223337-rdf.xml
RDF/JSON: 52383-1.0223337-rdf.json
Turtle: 52383-1.0223337-turtle.txt
N-Triples: 52383-1.0223337-rdf-ntriples.txt
Original Record: 52383-1.0223337-source.json
Full Text

Full Text

POSTER PRESENTATION Open AccessCD34 is required for the infiltration ofinflammatory cells into the mouse colon duringDSS-induced colitisSteven Maltby*, Carolin Wohlfarth, Michael R Hughes, Kelly M McNagnyFrom AllerGen NCE Inc.’s Fifth Annual Research Conference: Innovation from Cell to SocietyQuébec City, QC, Canada. 7-9 February 2010Objective/purposeEosinophil infiltration of gut tissue plays a key role in thepathogenesis of inflammatory bowel diseases (IBD), suchas ulcerative colitis. Using a model of allergic asthma, wepreviously demonstrated that eosinophil migrationrequires surface expression of the sialomucin CD34, andthat Cd34 deletion dampens asthmatic responses in mice.Since CD34 is critical for eosinophil migration, we inves-tigated a role for CD34 in the migration of inflammatorycells into the colon using a mouse model of IBD.MethodsTo induce ulcerative colitis, we treated animals with 3.5%dextran sodium sulfate (DSS) and monitored the appear-ance of clinical symptoms including weight loss, rectalbleeding and diarrhea. Mice were sacrificed after eightdays of treatment and we measured colon length, enum-erated hematopoietic lineage subsets infiltrating gut tis-sue by flow cytometry and prepared colon sections forhistology to determine the severity of gut pathology. Inorder to determine the significance of CD34 expressionon hematopoietic cells in the development and progres-sion of IBD, we reconstituted wild type mice with Cd34-/-bone marrow to generate chimeras.FindingsWe found that Cd34-/- mice are highly resistant to DSS-induced IBD with significantly less weight loss andcolon shortening than wildtype controls. Histologicalanalysis of Cd34-/- colons revealed less crypt loss, lesstissue infiltrate, reduced tissue ulceration and overallreduced disease severity. We found that approximately40% of the infiltrating blood cells are eosinophils andperipheral eosinophil levels are reduced following dis-ease induction. Intriguingly, eosinophils harvested fromthe colon express high levels of CD34 and represent themajority of CD34+ cells within inflamed gut tissue. Pro-tection from DSS-induced IBD is largely recapitulated inmice reconstituted with Cd34-/- bone marrow, demon-strating the requirement for CD34 expression on hema-topoietic cells in mucosal inflammation.Deliverables and relevanceOur findings demonstrate a key role for CD34 on hemato-poietic cells in the pathology of ulcerative colitis. Gut eosi-nophils express high levels of CD34 and, similar to ourfindings in allergic asthma, we demonstrated that CD34 isrequired for optimal eosinophil migration in vivo andCd34 deletion results in decreased gut inflammation dur-ing IBD. Taken together, our findings highlight CD34 as apotential therapeutic target for IBD treatment and suggestthat therapies targeting CD34 may be sufficient to impaireosinophil infiltration into the colon.AcknowledgementsThe research was funded by the AllerGen Network Centre of Excellence(3.14). SM and MRH hold CIHR and Hearth & Stroke Transfusion ScienceFellowships from the Centre for Blood Research (UBC). Kelly McNagny is aMichael Smith Foundation Scholar (Senior) and Centre for Blood ResearchMember.Published: 26 November 2010doi:10.1186/1710-1492-6-S3-P23Cite this article as: Maltby et al.: CD34 is required for the infiltration ofinflammatory cells into the mouse colon during DSS-induced colitis.Allergy, Asthma & Clinical Immunology 2010 6(Suppl 3):P23.* Correspondence: smaltby@br.ubc.caThe Biomedical Research Centre, University of British Columbia, 2222 HealthSciences Mall, Vancouver, BC, V6T 1Z3, CanadaMaltby et al. Allergy, Asthma & Clinical Immunology 2010, 6(Suppl 3):P23http://www.aacijournal.com/content/6/S3/P23 ALLERGY, ASTHMA & CLINICAL IMMUNOLOGY© 2010 Maltby et al; licensee BioMed Central Ltd.


Citation Scheme:


Citations by CSL (citeproc-js)

Usage Statistics



Customize your widget with the following options, then copy and paste the code below into the HTML of your page to embed this item in your website.
                            <div id="ubcOpenCollectionsWidgetDisplay">
                            <script id="ubcOpenCollectionsWidget"
                            async >
IIIF logo Our image viewer uses the IIIF 2.0 standard. To load this item in other compatible viewers, use this url:


Related Items